United States Pharmacopoeia Convention

Printer-friendly version
144th session of the Executive Board<br>24 January - 1 February 2019
Agenda Item: 
6.2 Member State mechanism on substandard and falsified medical products

USP appreciates the opportunity to comment on the Director General’s report on the Member State mechanism on substandard and falsified medical products.
Everyone deserves access to medicines they can trust as a right, not a privilege. Yet increasingly, we see substandard and falsified medicines harming patients and threatening the public health.
We commend the WHO and Member States for the 2017 release of two landmark reports: one on the prevalence of substandard and falsified medicines and one on their socioeconomic and public health impact. These have generated greater awareness of the scope and scale of the problem, and the threat undermining progress across many areas of global health.
We congratulate the Director General for his leadership on this issue; we are inspired by the heads of State from the African member states who have elevated this issue to the highest levels.
As a committed partner to the Member State mechanism, USP serves as a technical resource to the Working Group of Activity C, improving Member States’ understanding of detection technologies. Through the Promoting the Quality of Medicines program supported by USAID, USP shares field reports with the Global Surveillance and Monitoring System and supports regulatory agencies to strengthen quality assurance systems.
We believe that it is time for the Member State Mechanism to widen the tent. As a partner of the Medicines We Can Trust campaign, a global movement to raise awareness of the importance of medicines quality and the impact poor-quality medicines have on people’s lives, we welcome the opportunity to collaborate in Activities D, E and F. With the active engagement of scientists, practitioners, patients and consumers, supporting the work of regulators and public health advocates, we can stem the tide of SF medicines.